Search

An indictment was returned today by a federal grand jury in New Jersey, charging the former chief executive officer of a publicly-traded health care company (referred to in the indictment as Company-1) with two counts of securities fraud for his alleged participation in a scheme to mislead investors about Company-1’s procurement of COVID-19 rapid test kits in the early days of the COVID-19 pandemic.

We conducted a limited review of the New Jersey COVID-19 CARES Act Marine Fisheries Assistance Grant Program administered by the New Jersey Department of Environmental Protection (DEP). We evaluated whether DEP took appropriate steps to prevent and detect fraud, waste, abuse, and improper payments in its administration of the program; whether program recipients disclosed other sources of COVID-19 assistance received; whether program recipients had been made “more than whole” by their receipt of assistance from the Fishery Program; and whether program recipients had accurately documented their...